Incidence of Neuropathy with Weekly Paclitaxel and Role of Oral Glutamine Supplementation for Prevention of Paclitaxel Induced Peripheral Neuropathy Randomized Controlled Trial

Abstract

Background: Peripheral neuropathy is damage to the peripheral nerve. The most common cause of neuropathy is paclitaxel. Several avenues have been explored to ameliorate the neurotoxicity associated with paclitaxel. Clinical studies have assessed the efficacy of glutamine with different doses and schedules to prevent gastrointestinal toxicity (mucositis, diarrhea) and peripheral neuropathy in patients receiving a variety of chemotherapy agents or radiation therapy and found that glutamine can prevent paclitaxel-induced peripheral neuropathy. Methods: Total of 50 patients, aged 30 or more with diagnosis of cancer and fulfilling the inclusion and exclusion criteria, formed the study population. We assigned 25 patients to the glutamine group and 25 patients to no glutamine group. All patients received weekly paclitaxel. Results:: The incidence of neuropathy of all grades at 3 months was 78% and at 6 months was 80%.In this study, most common symptom reported was numbness in toes (74%). In this study, Grade 1 was the most common grade of symptom reported by the patient (40%–50%). 2nd, 3rd, and 4th most common grade of symptom reported by the patient was Grade 0, Grade 2, and Grade 3, respectively. There was no Grade 4 symptom reported by any patient. All the symptoms were statistically comparable in both groups (Myalgias: P = 0.066, Arthralgia: P = 0.93, Dysesthesia: P = 0.82, Paresthesia: P = 0.92, Numbness fingers: P = 0.97, Numbness toes: P = 0.60). In our study, there was no incidence of cranial nerve weakness or any incidence of the postural drop. The electrophysiological study is the best tool available and can detect neuropathy at the very earlier stage even when the clinical exam is negative. Apart from that nature of neuropathy can be determined but grading is not possible which makes very difficult to decide on follow-up examinations when the physician should intervene. Moreover, there are fluctuations in SNAP and CMAP, and these fluctuations are most probably related to the innate variability of serial nerve conduction study parameters, particularly motor and sensory amplitude. Glutamine did not prevent neurotoxicity induced by weekly paclitaxel.

Keywords

Glutamine supplementation for prevention of paclitaxel induced neuropathy - Incidence of neuropathy with weekly paclitaxel - Paclitaxel induced neuropathy

Publikationsverlauf

Artikel online veröffentlicht:
17. Juni 2021

• References

• 1 Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006; 33: 15-49
• 2 Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A. et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368-73
• 3 Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993; 15: 107-15
• 4 Bitton RJ, Figg WD, Reed E. et al. A preliminary risk-benefit assessment of paclitaxel. Drug Saf 1995; 12: 196-208
• 5 Balmaceda C, Freilich RJ, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115-8
• 6 Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME. et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66
• 7 Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH. et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project protocol B-26. J Clin Oncol 1999; 17: 3403-11
• 8 Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP. et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003; 14: 785-92
• 9 Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM. et al. The use of Vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 2011; 19: 1769-77
• 10 Savarese D, Boucher J, Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 1998; 16: 3918-9
• 11 Kautio AL, Haanpää M, Leminen A, Kautiainen H, Saarto T. et al. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptom. Anticancer Res 2009; 29: 2601-6
• 12 Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA. et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110: 2110-8
• 13 Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL. et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005; 17: 271-6
• 14 Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94
• 15 Pace A, Bove L, Aloe A, Nardi M, Pietrangeli A. Paclitaxel neurotoxicity: Clinical and neur18, Princeton NJ: Bristol-Myers Squibb. Taxol Prescribing Information. pathophysiologic study of 23 patients. Ital J Neurol Sci 1997; 18: 73-9
• 16 Taxol Prescribing Information. Princeton NJ: Bristol-Myers Squibb; 2011.
• 17 Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK. et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-9
• 18 Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D. et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-8
• 19 Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-71
• 20 Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G. et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: A schedule or a dose issue?. Clin Breast Cancer 2007; 7: 550-4
• 21 Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: A new approach in clinical testing. Muscle Nerve 2000; 23: 339-409
• 22 Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T. et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-7
• 23 Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF. et al. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: A meta-analysis. Ann Oncol 2013; 24: 171-8
• 24 Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P. et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014; 32: 997-1005
• 25 Chroni E, Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T. et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006; 67: 2253-5
• 26 Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB. et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112: 2802-8
• 27 Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D. et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7: 1192-7
• 28 Loven D, Levavi H, Sabach G, Zart R, Andras M, Fishman A. et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care (Engl) 2009; 18: 78-83
• 29 Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS. et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12: 312-9